TNF and myeloid sarcoma: In the context of our findings regarding the impact of citrullinated myelin on microglial activation, this suggests that anti-TNFα therapies should be reconsidered in specific MS patients with aggressive disease, perhaps as a “rescue” intervention to interfere with an acute microglial-driven inflammatory process.